# SPEARHEAD-3 Pediatric Study

Source: https://onco.cc/trials/nct05642455/  
OnCo record `nct05642455` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Afamitresgene autoleucel in osteosarcoma, run by USWM CT, LLC, now recruiting.

## Summary

SPEARHEAD-3 Pediatric Study is a phase 1/2 interventional study registered as NCT05642455 by USWM CT, LLC, with 20 participants planned, started 2023-09-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: Afamitresgene autoleucel. Conditions listed: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05642455
- Phase: 1/2
- Setting: A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors
- Sponsor: USWM CT, LLC
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT05642455: https://clinicaltrials.gov/study/NCT05642455

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Afamitresgene autoleucel](https://onco.cc/drugs/afamitresgene-autoleucel/)

---
JSON: https://onco.cc/api/v1/entities/nct05642455.json